The ubiquitin proteasome system - Implications for cell cycle control and the targeted treatment of cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 1, 2014, Pages 150-162

  Bassermann, Florian ^a   Eichner, Ruth ^a   Pagano, Michele ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

APC C; Cancer; Cell cycle; F box; SCF complex; Ubiquitin proteasome system

Indexed keywords

ANAPHASE PROMOTING COMPLEX; BETATRCP PROTEIN; BORTEZOMIB; CELL CYCLE PROTEIN 20; CYCLIN DEPENDENT KINASE 2; F BOX PROTEIN; FBXO9 PROTEIN; FBXW7 PROTEIN; GROWTH FACTOR; INITIATION FACTOR 4A; ONCOPROTEIN; PDCD4 PROTEIN; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UVOMORULIN; VPU PROTEIN;

ANAPHASE; BREAST CANCER; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; DNA DAMAGE; DNA DAMAGE CHECKPOINT; ENZYME INACTIVATION; ENZYME INHIBITION; GENE MUTATION; HEAD AND NECK TUMOR; LARGE CELL LYMPHOMA; LUNG CANCER; M PHASE CELL CYCLE CHECKPOINT; METAPHASE; MITOSIS; MOLECULARLY TARGETED THERAPY; NUTRIENT; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROMETAPHASE; REVIEW; STOMACH CANCER; UBIQUITINATION;

EID: 84890243576     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.02.028     Document Type: Review

References (192)

1. Murray A.W. Recycling the cell cycle: cyclins revisited. Cell 2004, 116:221-234.
2. Glotzer M., Murray A.W., Kirschner M.W. Cyclin is degraded by the ubiquitin pathway. Nature 1991, 349:132-138.
3. Skaar J.R., Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr. Opin. Cell Biol. 2009, 21:816-824.
4. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
5. Clague M.J., Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell 2010, 143:682-685.
6. Behrends C., Harper J.W. Constructing and decoding unconventional ubiquitin chains. Nat. Struct. Mol. Biol. 2011, 18:520-528.
7. Xu P., Duong D.M., Seyfried N.T., Cheng D., Xie Y., Robert J., Rush J., Hochstrasser M., Finley D., Peng J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009, 137:133-145.
8. Jacobson A.D., Zhang N.Y., Xu P., Han K.J., Noone S., Peng J., Liu C.W. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26s proteasome. J. Biol. Chem. 2009, 284:35485-35494.
9. Clague M.J., Coulson J.M., Urbe S. Cellular functions of the DUBs. J. Cell Sci. 2012, 125:277-286.
10. Li W., Bengtson M.H., Ulbrich A., Matsuda A., Reddy V.A., Orth A., Chanda S.K., Batalov S., Joazeiro C.A. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 2008, 3:e1487.
11. Metzger M.B., Hristova V.A., Weissman A.M. HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell Sci. 2012, 125:531-537.
12. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
13. Cardozo T., Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 2004, 5:739-751.
14. Zheng N., Schulman B.A., Song L., Miller J.J., Jeffrey P.D., Wang P., Chu C., Koepp D.M., Elledge S.J., Pagano M., Conaway R.C., Conaway J.W., Harper J.W., Pavletich N.P. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416:703-709.
15. Bai C., Sen P., Hofmann K., Ma L., Goebl M., Harper J.W., Elledge S.J. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996, 86:263-274.
16. Cenciarelli C., Chiaur D.S., Guardavaccaro D., Parks W., Vidal M., Pagano M. Identification of a family of human F-box proteins. Curr. Biol. 1999, 9:1177-1179.
17. Jin J., Cardozo T., Lovering R.C., Elledge S.J., Pagano M., Harper J.W. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004, 18:2573-2580.
18. Silverman J.S., Skaar J.R., Pagano M. SCF ubiquitin ligases in the maintenance of genome stability. Trends Biochem. Sci. 2012, 37:66-73.
19. van Leuken R., Clijsters L., Wolthuis R. To cell cycle, swing the APC/C. Biochim. Biophys. Acta 2008, 1786:49-59.
20. Acquaviva C., Pines J. The anaphase-promoting complex/cyclosome: APC/C. J. Cell Sci. 2006, 119:2401-2404.
21. Li M., Zhang P. The function of APC/CCdh1 in cell cycle and beyond. Cell Div. 2009, 4:2.
22. Nakayama K.I., Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 2005, 16:323-333.
23. Mailand N., Diffley J.F. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 2005, 122:915-926.
24. Li M., Shin Y.H., Hou L., Huang X., Wei Z., Klann E., Zhang P. The adaptor protein of the anaphase promoting complex Cdh1 is essential in maintaining replicative lifespan and in learning and memory. Nat. Cell Biol. 2008, 10:1083-1089.
25. Albanese C., Johnson J., Watanabe G., Eklund N., Vu D., Arnold A., Pestell R.G. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 1995, 270:23589-23597.
26. Bashir T., Pagano M. Don't skip the G1 phase: how APC/CCdh1 keeps SCFSKP2 in check. Cell Cycle 2004, 3:850-852.
27. Bashir T., Dorrello N.V., Amador V., Guardavaccaro D., Pagano M. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004, 428:190-193.
28. Wei W., Ayad N.G., Wan Y., Zhang G.J., Kirschner M.W., Kaelin W.G. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 2004, 428:194-198.
29. Donzelli M., Squatrito M., Ganoth D., Hershko A., Pagano M., Draetta G.F. Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 2002, 21:4875-4884.
30. Skaar J.R., Pagano M. Cdh1: a master G0/G1 regulator. Nat. Cell Biol. 2008, 10:755-757.
31. King R.W., Peters J.M., Tugendreich S., Rolfe M., Hieter P., Kirschner M.W. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 1995, 81:279-288.
32. Geley S., Kramer E., Gieffers C., Gannon J., Peters J.M., Hunt T. Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J. Cell Biol. 2001, 153:137-148.
33. Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., Furukawa K., Urano T. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000, 19:2812-2819.
34. Castro A., Arlot-Bonnemains Y., Vigneron S., Labbe J.C., Prigent C., Lorca T. APC/fizzy-related targets aurora-A kinase for proteolysis. EMBO Rep. 2002, 3:457-462.
35. Stewart S., Fang G. Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res. 2005, 65:8730-8735.
36. Lindon C., Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J. Cell Biol. 2004, 164:233-241.
37. Garcia-Higuera I., Manchado E., Dubus P., Canamero M., Mendez J., Moreno S., Malumbres M. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat. Cell Biol. 2008, 10:802-811.
38. Fernandez-Saiz V., Targosz B.S., Lemeer S., Eichner R., Langer C., Bullinger L., Reiter C., Slotta-Huspenina J., Schroeder S., Knorn A.M., Kurutz J., Peschel C., Pagano M., Kuster B., Bassermann F. SCF(Fbxo9) and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat. Cell Biol. 2013, 15:72-81.
39. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471.
40. Dehan E., Bassermann F., Guardavaccaro D., Vasiliver-Shamis G., Cohen M., Lowes K.N., Dustin M., Huang D.C., Taunton J., Pagano M. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol. Cell 2009, 33:109-116.
41. Duan S., Skaar J.R., Kuchay S., Toschi A., Kanarek N., Ben-Neriah Y., Pagano M. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol. Cell 2011, 44:317-324.
42. Gao D., Inuzuka H., Tan M.K., Fukushima H., Locasale J.W., Liu P., Wan L., Zhai B., Chin Y.R., Shaik S., Lyssiotis C.A., Gygi S.P., Toker A., Cantley L.C., Asara J.M., Harper J.W., Wei W. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol. Cell 2011, 44:290-303.
43. Rape M., Kirschner M.W. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 2004, 432:588-595.
44. Listovsky T., Oren Y.S., Yudkovsky Y., Mahbubani H.M., Weiss A.M., Lebendiker M., Brandeis M. Mammalian Cdh1/Fzr mediates its own degradation. EMBO J. 2004, 23:1619-1626.
45. Lukas C., Sorensen C.S., Kramer E., Santoni-Rugiu E., Lindeneg C., Peters J.M., Bartek J., Lukas J. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999, 401:815-818.
46. Benmaamar R., Pagano M. Involvement of the SCF complex in the control of Cdh1 degradation in S-phase. Cell Cycle 2005, 4:1230-1232.
47. Miller J.J., Summers M.K., Hansen D.V., Nachury M.V., Lehman N.L., Loktev A., Jackson P.K. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 2006, 20:2410-2420.
48. Hsu J.Y., Reimann J.D., Sorensen C.S., Lukas J., Jackson P.K. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat. Cell Biol. 2002, 4:358-366.
49. Geng Y., Eaton E.N., Picon M., Roberts J.M., Lundberg A.S., Gifford A., Sardet C., Weinberg R.A. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 1996, 12:1173-1180.
50. Schulze A., Zerfass K., Spitkovsky D., Middendorp S., Berges J., Helin K., Jansen-Durr P., Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11264-11268.
51. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 1999, 9:661-664.
52. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1999, 1:193-199.
53. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685.
54. Sutterluty H., Chatelain E., Marti A., Wirbelauer C., Senften M., Muller U., Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell Biol. 1999, 1:207-214.
55. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997, 11:1464-1478.
56. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997, 16:5334-5344.
57. Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G.F., Hershko A., Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999, 13:1181-1189.
58. Ganoth D., Bornstein G., Ko T.K., Larsen B., Tyers M., Pagano M., Hershko A. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat. Cell Biol. 2001, 3:321-324.
59. Spruck C., Strohmaier H., Watson M., Smith A.P., Ryan A., Krek T.W., Reed S.I. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol. Cell 2001, 7:639-650.
60. Bornstein G., Bloom J., Sitry-Shevah D., Nakayama K., Pagano M., Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 2003, 278:25752-25757.
61. Kamura T., Hara T., Kotoshiba S., Yada M., Ishida N., Imaki H., Hatakeyama S., Nakayama K., Nakayama K.I. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10231-10236.
62. Hershko D.D. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008, 112:1415-1424.
63. Lin D.I., Barbash O., Kumar K.G., Weber J.D., Harper J.W., Klein-Szanto A.J., Rustgi A., Fuchs S.Y., Diehl J.A. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol. Cell 2006, 24:355-366.
64. Clurman B.E., Sheaff R.J., Thress K., Groudine M., Roberts J.M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996, 10:1979-1990.
65. Koepp D.M., Schaefer L.K., Ye X., Keyomarsi K., Chu C., Harper J.W., Elledge S.J. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001, 294:173-177.
66. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
67. Zeng Y., Forbes K.C., Wu Z., Moreno S., Piwnica-Worms H., Enoch T. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature 1998, 395:507-510.
68. Busino L., Donzelli M., Chiesa M., Guardavaccaro D., Ganoth D., Dorrello N.V., Hershko A., Pagano M., Draetta G.F. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003, 426:87-91.
69. Smits V.A., Klompmaker R., Arnaud L., Rijksen G., Nigg E.A., Medema R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2000, 2:672-676.
70. Bassermann F., Frescas D., Guardavaccaro D., Busino L., Peschiaroli A., Pagano M. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008, 134:256-267.
71. Bassermann F., Pagano M. Dissecting the role of ubiquitylation in the DNA damage response checkpoint in G2. Cell Death Differ. 2010, 17:78-85.
72. Peschiaroli A., Dorrello N.V., Guardavaccaro D., Venere M., Halazonetis T., Sherman N.E., Pagano M. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol. Cell 2006, 23:319-329.
73. Mailand N., Bekker-Jensen S., Bartek J., Lukas J. Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol. Cell 2006, 23:307-318.
74. Kruiswijk F., Yuniati L., Magliozzi R., Low T.Y., Lim R., Bolder R., Mohammed S., Proud C.G., Heck A.J., Pagano M., Guardavaccaro D. Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress. Sci. Signal. 2012, 5:ra40.
75. D'Angiolella V., Donato V., Forrester F.M., Jeong Y.T., Pellacani C., Kudo Y., Saraf A., Florens L., Washburn M.P., Pagano M. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 2012, 149:1023-1034.
76. D'Angiolella V., Donato V., Vijayakumar S., Saraf A., Florens L., Washburn M.P., Dynlacht B., Pagano M. SCF (Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 2010, 466:138-142.
77. Watanabe N., Arai H., Nishihara Y., Taniguchi M., Hunter T., Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4419-4424.
78. Seki A., Coppinger J.A., Jang C.Y., Yates J.R., Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008, 320:1655-1658.
79. Bassermann F., von Klitzing C., Munch S., Bai R.Y., Kawaguchi H., Morris S.W., Peschel C., Duyster J. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 2005, 122:45-57.
80. Bassermann F., von Klitzing C., Illert A.L., Munch S., Morris S.W., Pagano M., Peschel C., Duyster J. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J. Biol. Chem. 2007, 282:15965-15972.
81. Illert A.L., Zech M., Moll C., Albers C., Kreutmair S., Peschel C., Bassermann F., Duyster J. Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M. J. Biol. Chem. 2012, 287:37997-38005.
82. Margottin-Goguet F., Hsu J.Y., Loktev A., Hsieh H.M., Reimann J.D., Jackson P.K. Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev. Cell 2003, 4:813-826.
83. Guardavaccaro D., Kudo Y., Boulaire J., Barchi M., Busino L., Donzelli M., Margottin-Goguet F., Jackson P.K., Yamasaki L., Pagano M. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev. Cell 2003, 4:799-812.
84. Fang G., Yu H., Kirschner M.W. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev. 1998, 12:1871-1883.
85. Sudakin V., Chan G.K., Yen T.J. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J. Cell Biol. 2001, 154:925-936.
86. Braunstein I., Miniowitz S., Moshe Y., Hershko A. Inhibitory factors associated with anaphase-promoting complex/cylosome in mitotic checkpoint. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4870-4875.
87. Nilsson J., Yekezare M., Minshull J., Pines J. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat. Cell Biol. 2008, 10:1411-1420.
88. Ge S., Skaar J.R., Pagano M. APC/C- and Mad2-mediated degradation of Cdc20 during spindle checkpoint activation. Cell Cycle 2009, 8:167-171.
89. D'Angiolella V., Mari C., Nocera D., Rametti L., Grieco D. The spindle checkpoint requires cyclin-dependent kinase activity. Genes Dev. 2003, 17:2520-2525.
90. Chung E., Chen R.H. Phosphorylation of Cdc20 is required for its inhibition by the spindle checkpoint. Nat. Cell Biol. 2003, 5:748-753.
91. Tang Z., Shu H., Oncel D., Chen S., Yu H. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol. Cell 2004, 16:387-397.
92. Guardavaccaro D., Frescas D., Dorrello N.V., Peschiaroli A., Multani A.S., Cardozo T., Lasorella A., Iavarone A., Chang S., Hernando E., Pagano M. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 2008, 452:365-369.
93. Amador V., Ge S., Santamaria P.G., Guardavaccaro D., Pagano M. APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol. Cell 2007, 27:462-473.
94. Pfleger C.M., Kirschner M.W. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. Genes Dev. 2000, 14:655-665.
95. Reis A., Levasseur M., Chang H.Y., Elliott D.J., Jones K.T. The CRY box: a second APCcdh1-dependent degron in mammalian cdc20. EMBO Rep. 2006, 7:1040-1045.
96. Di Fiore B., Pines J. How cyclin A destruction escapes the spindle assembly checkpoint. J. Cell Biol. 2010, 190:501-509.
97. Hayes M.J., Kimata Y., Wattam S.L., Lindon C., Mao G., Yamano H., Fry A.M. Early mitotic degradation of Nek2A depends on Cdc20-independent interaction with the APC/C. Nat. Cell Biol. 2006, 8:607-614.
98. van Zon W., Wolthuis R.M. Cyclin A and Nek2A: APC/C-Cdc20 substrates invisible to the mitotic spindle checkpoint. Biochem. Soc. Trans. 2010, 38:72-77.
99. Varetti G., Guida C., Santaguida S., Chiroli E., Musacchio A. Homeostatic control of mitotic arrest. Mol. Cell 2011, 44:710-720.
100. Foe I.T., Foster S.A., Cheung S.K., DeLuca S.Z., Morgan D.O., Toczyski D.P. Ubiquitination of Cdc20 by the APC occurs through an intramolecular mechanism. Curr. Biol. 2011, 21:1870-1877.
101. Reddy S.K., Rape M., Margansky W.A., Kirschner M.W. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 2007, 446:921-925.
102. Miniowitz-Shemtov S., Teichner A., Sitry-Shevah D., Hershko A. ATP is required for the release of the anaphase-promoting complex/cyclosome from inhibition by the mitotic checkpoint. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5351-5356.
103. Zou H., McGarry T.J., Bernal T., Kirschner M.W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999, 285:418-422.
104. Peters J.M. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat. Rev. Mol. Cell Biol. 2006, 7:644-656.
105. Hauf S., Waizenegger I.C., Peters J.M. Cohesin cleavage by separase required for anaphase and cytokinesis in human cells. Science 2001, 293:1320-1323.
106. Karamysheva Z., Diaz-Martinez L.A., Crow S.E., Li B., Yu H. Multiple anaphase-promoting complex/cyclosome degrons mediate the degradation of human Sgo1. J. Biol. Chem. 2009, 284:1772-1780.
107. Kitajima T.S., Kawashima S.A., Watanabe Y. The conserved kinetochore protein shugoshin protects centromeric cohesion during meiosis. Nature 2004, 427:510-517.
108. Sudakin V., Ganoth D., Dahan A., Heller H., Hershko J., Luca F.C., Ruderman J.V., Hershko A. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol. Biol. Cell 1995, 6:185-197.
109. Raff J.W., Jeffers K., Huang J.Y. The roles of Fzy/Cdc20 and Fzr/Cdh1 in regulating the destruction of cyclin B in space and time. J. Cell Biol. 2002, 157:1139-1149.
110. den Elzen N., Pines J. Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. J. Cell Biol. 2001, 153:121-136.
111. Clute P., Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat. Cell Biol. 1999, 1:82-87.
112. Seki A., Coppinger J.A., Du H., Jang C.Y., Yates J.R., Fang G. Plk1- and beta-TrCP-dependent degradation of Bora controls mitotic progression. J. Cell Biol. 2008, 181:65-78.
113. Chan E.H., Santamaria A., Sillje H.H., Nigg E.A. Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora. Chromosoma 2008, 117:457-469.
114. McGarry T.J., Kirschner M.W. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 1998, 93:1043-1053.
115. Kramer E.R., Scheuringer N., Podtelejnikov A.V., Mann M., Peters J.M. Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol. Biol. Cell 2000, 11:1555-1569.
116. Zur A., Brandeis M. Timing of APC/C substrate degradation is determined by fzy/fzr specificity of destruction boxes. EMBO J. 2002, 21:4500-4510.
117. Rape M., Reddy S.K., Kirschner M.W. The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell 2006, 124:89-103.
118. Sumara I., Maerki S., Peter M. E3 ubiquitin ligases and mitosis: embracing the complexity. Trends Cell Biol. 2008, 18:84-94.
119. Angers S., Li T., Yi X., MacCoss M.J., Moon R.T., Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006, 443:590-593.
120. He Y.J., McCall C.M., Hu J., Zeng Y., Xiong Y. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 2006, 20:2949-2954.
121. Lee J., Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol. Cell 2007, 26:775-780.
122. Shibata E., Abbas T., Huang X., Wohlschlegel J.A., Dutta A. Selective ubiquitylation of p21 and Cdt1 by UBCH8 and UBE2G ubiquitin-conjugating enzymes via the CRL4Cdt2 ubiquitin ligase complex. Mol. Cell. Biol. 2011, 31:3136-3145.
123. Nishitani H., Sugimoto N., Roukos V., Nakanishi Y., Saijo M., Obuse C., Tsurimoto T., Nakayama K.I., Nakayama K., Fujita M., Lygerou Z., Nishimoto T. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J. 2006, 25:1126-1136.
124. Arias E.E., Walter J.C. PCNA functions as a molecular platform to trigger Cdt1 destruction and prevent re-replication. Nat. Cell Biol. 2006, 8:84-90.
125. Jin J., Arias E.E., Chen J., Harper J.W., Walter J.C. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell 2006, 23:709-721.
126. Zhong W., Feng H., Santiago F.E., Kipreos E.T. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. Nature 2003, 423:885-889.
127. Hu J., McCall C.M., Ohta T., Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat. Cell Biol. 2004, 6:1003-1009.
128. Li X., Zhao Q., Liao R., Sun P., Wu X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J. Biol. Chem. 2003, 278:30854-30858.
129. Abbas T., Sivaprasad U., Terai K., Amador V., Pagano M., Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev. 2008, 22:2496-2506.
130. Abbas T., Shibata E., Park J., Jha S., Karnani N., Dutta A. CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Mol. Cell 2010, 40:9-21.
131. Centore R.C., Havens C.G., Manning A.L., Li J.M., Flynn R.L., Tse A., Jin J., Dyson N.J., Walter J.C., Zou L. CRL4(Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase. Mol. Cell 2010, 40:22-33.
132. Jorgensen S., Eskildsen M., Fugger K., Hansen L., Larsen M.S., Kousholt A.N., Syljuasen R.G., Trelle M.B., Jensen O.N., Helin K., Sorensen C.S. SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation. J. Cell Biol. 2011, 192:43-54.
133. T. Abbas, A. Mueller, E. Shibata, M. Keaton, M. Rossi, A. Dutta, CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration, Mol. Cell (in press), (Epub 2013 Mar 7). http://dx.doi.org/10.1016/j.molcel.2013.02.003.
134. M. Rossi, S. Duan, Y.T. Jeong, M. Horn, A. Saraf, L. Florens, M.P. Washburn, A. Antebi, M. Pagano, Regulation of the CRL4Cdt2 ubiquitin ligase and cell cycle exit by the SCFFbxo11 ubiquitin ligase, Mol. Cell (in press), (Epub 2013 Mar 7). http://dx.doi.org/10.1016/j.molcel.2013.02.004.
135. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005, 23:630-639.
136. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San Miguel J.F., Palumbo A., Harousseau J.L. Proteasome inhibitors in multiple myeloma: 10years later. Blood 2012, 120:947-959.
137. Nakayama K.I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006, 6:369-381.
138. Skaar J.R., D'Angiolella V., Pagan J.K., Pagano M. SnapShot: F box proteins II. Cell 2009, 137:1358. (1358 e1351).
139. Masuda T.A., Inoue H., Sonoda H., Mine S., Yoshikawa Y., Nakayama K., Nakayama K., Mori M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002, 62:3819-3825.
140. Masuda T.A., Inoue H., Nishida K., Sonoda H., Yoshikawa Y., Kakeji Y., Utsunomiya T., Mori M. Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin. Cancer Res. 2003, 9:5693-5698.
141. Shapira M., Ben-Izhak O., Linn S., Futerman B., Minkov I., Hershko D.D. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005, 103:1336-1346.
142. Signoretti S., Di Marcotullio L., Richardson A., Ramaswamy S., Isaac B., Rue M., Monti F., Loda M., Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 2002, 110:633-641.
143. Latres E., Chiarle R., Schulman B.A., Pavletich N.P., Pellicer A., Inghirami G., Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2515-2520.
144. Shim E.H., Johnson L., Noh H.L., Kim Y.J., Sun H., Zeiss C., Zhang H. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 2003, 63:1583-1588.
145. Timmerbeul I., Garrett-Engele C.M., Kossatz U., Chen X., Firpo E., Grunwald V., Kamino K., Wilkens L., Lehmann U., Buer J., Geffers R., Kubicka S., Manns M.P., Porter P.L., Roberts J.M., Malek N.P. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14009-14014.
146. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., Cordon-Cardo C., Teruya-Feldstein J., Pandolfi P.P. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
147. Lee S.H., McCormick F. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J. Mol. Med. 2005, 83:296-307.
148. Katagiri Y., Hozumi Y., Kondo S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J. Dermatol. Sci. 2006, 42:215-224.
149. Kudo Y., Kitajima S., Ogawa I., Kitagawa M., Miyauchi M., Takata T. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol. Cancer Ther. 2005, 4:471-476.
150. Barry M., Fruh K., Sci S.T.K.E. Viral modulators of cullin RING ubiquitin ligases: culling the host defense. Sci. STKE 2006, pe21.
151. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
152. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., Harper J.W. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999, 13:270-283.
153. Tang W., Li Y., Yu D., Thomas-Tikhonenko A., Spiegelman V.S., Fuchs S.Y. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res. 2005, 65:1904-1908.
154. Kudo Y., Guardavaccaro D., Santamaria P.G., Koyama-Nasu R., Latres E., Bronson R., Yamasaki L., Pagano M. Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol. Cell. Biol. 2004, 24:8184-8194.
155. Ougolkov A., Zhang B., Yamashita K., Bilim V., Mai M., Fuchs S.Y., Minamoto T. Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J. Natl. Cancer Inst. 2004, 96:1161-1170.
156. Muerkoster S., Arlt A., Sipos B., Witt M., Grossmann M., Kloppel G., Kalthoff H., Folsch U.R., Schafer H. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 2005, 65:1316-1324.
157. Belaidouni N., Peuchmaur M., Perret C., Florentin A., Benarous R., Besnard-Guerin C. Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice. Oncogene 2005, 24:2271-2276.
158. Besnard-Guerin C., Belaidouni N., Lassot I., Segeral E., Jobart A., Marchal C., Benarous R. HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J. Biol. Chem. 2004, 279:788-795.
159. Palumbo A., Anderson K. Multiple myeloma. N. Engl. J. Med. 2011, 364:1046-1060.
160. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl. Cancer Inst. 2011, 103:1007-1017.
161. Battistutta R. Protein kinase CK2 in health and disease: structural bases of protein kinase CK2 inhibition. Cell Mol. Life Sci. 2009, 66:1868-1889.
162. Busino L., Millman S.E., Scotto L., Kyratsous C.A., Basrur V., O'Connor O., Hoffmann A., Elenitoba-Johnson K.S., Pagano M. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat. Cell Biol. 2012, 14:375-385.
163. Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., Ferrando A., Aifantis I. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 2007, 204:1825-1835.
164. Rajagopalan H., Jallepalli P.V., Rago C., Velculescu V.E., Kinzler K.W., Vogelstein B., Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428:77-81.
165. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., Hardwick J., Welcker M., Meijerink J.P., Pieters R., Draetta G., Sears R., Clurman B.E., Look A.T. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007, 204:1813-1824.
166. Chapman M.A., Lawrence M.S., Keats J.J., Cibulskis K., Sougnez C., Schinzel A.C., Harview C.L., Brunet J.P., Ahmann G.J., Adli M., Anderson K.C., Ardlie K.G., Auclair D., Baker A., Bergsagel P.L., Bernstein B.E., Drier Y., Fonseca R., Gabriel S.B., Hofmeister C.C., Jagannath S., Jakubowiak A.J., Krishnan A., Levy J., Liefeld T., Lonial S., Mahan S., Mfuko B., Monti S., Perkins L.M., Onofrio R., Pugh T.J., Rajkumar S.V., Ramos A.H., Siegel D.S., Sivachenko A., Stewart A.K., Trudel S., Vij R., Voet D., Winckler W., Zimmerman T., Carpten J., Trent J., Hahn W.C., Garraway L.A., Meyerson M., Lander E.S., Getz G., Golub T.R. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
167. Duan S., Cermak L., Pagan J.K., Rossi M., Martinengo C., di Celle P.F., Chapuy B., Shipp M., Chiarle R., Pagano M. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012, 481:90-93.
168. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., Cruz-Gordillo P., Knoechel B., Asmann Y.W., Slager S.L., Novak A.J., Dogan A., Ansell S.M., Link B.K., Zou L., Gould J., Saksena G., Stransky N., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Hernandez-Lemus E., Schwarz-Cruz y Celis A., Imaz-Rosshandler I., Ojesina A.I., Jung J., Pedamallu C.S., Lander E.S., Habermann T.M., Cerhan J.R., Shipp M.A., Getz G., Golub T.R. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. U. S. A. 2012, 3879-3884.
169. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
170. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortes M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L.A., Grandis J.R. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
171. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., Yue P., Haverty P.M., Bourgon R., Zheng J., Moorhead M., Chaudhuri S., Tomsho L.P., Peters B.A., Pujara K., Cordes S., Davis D.P., Carlton V.E., Yuan W., Li L., Wang W., Eigenbrot C., Kaminker J.S., Eberhard D.A., Waring P., Schuster S.C., Modrusan Z., Zhang Z., Stokoe D., de Sauvage F.J., Faham M., Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
172. Barbash O., Zamfirova P., Lin D.I., Chen X., Yang K., Nakagawa H., Lu F., Rustgi A.K., Diehl J.A. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 2008, 14:68-78.
173. Barbash O., Diehl J.A. SCF(Fbx4/alphaB-crystallin) E3 ligase: when one is not enough. Cell Cycle 2008, 7:2983-2986.
174. Fu J., Qiu H., Cai M., Pan Y., Cao Y., Liu L., Yun J., Zhang C.Z. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci. 2013, (Epub 2013 Feb 17). 10.1111/cas.12100.
175. Yang Y., Kitagaki J., Dai R.M., Tsai Y.C., Lorick K.L., Ludwig R.L., Pierre S.A., Jensen J.P., Davydov I.V., Oberoi P., Li C.C., Kenten J.H., Beutler J.A., Vousden K.H., Weissman A.M. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 2007, 67:9472-9481.
176. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., Brownell J.E., Burke K.E., Cardin D.P., Critchley S., Cullis C.A., Doucette A., Garnsey J.J., Gaulin J.L., Gershman R.E., Lublinsky A.R., McDonald A., Mizutani H., Narayanan U., Olhava E.J., Peluso S., Rezaei M., Sintchak M.D., Talreja T., Thomas M.P., Traore T., Vyskocil S., Weatherhead G.S., Yu J., Zhang J., Dick L.R., Claiborne C.F., Rolfe M., Bolen J.B., Langston S.P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
177. Goldenberg S.J., Cascio T.C., Shumway S.D., Garbutt K.C., Liu J., Xiong Y., Zheng N. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 2004, 119:517-528.
178. Duda D.M., Borg L.A., Scott D.C., Hunt H.W., Hammel M., Schulman B.A. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008, 134:995-1006.
179. Soucy T.A., Smith P.G., Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin. Cancer Res. 2009, 15:3912-3916.
180. Swords R.T., Kelly K.R., Smith P.G., Garnsey J.J., Mahalingam D., Medina E., Oberheu K., Padmanabhan S., O'Dwyer M., Nawrocki S.T., Giles F.J., Carew J.S. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010, 115:3796-3800.
181. Ye Y., Rape M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 2009, 10:755-764.
182. Ceccarelli D.F., Tang X., Pelletier B., Orlicky S., Xie W., Plantevin V., Neculai D., Chou Y.C., Ogunjimi A., Al-Hakim A., Varelas X., Koszela J., Wasney G.A., Vedadi M., Dhe-Paganon S., Cox S., Xu S., Lopez-Girona A., Mercurio F., Wrana J., Durocher D., Meloche S., Webb D.R., Tyers M., Sicheri F. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 2011, 145:1075-1087.
183. Gonzalez-Ruiz D., Gohlke H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem. 2006, 13:2607-2625.
184. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
185. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006, 13:921-926.
186. Shangary S., Qin D., McEachern D., Liu M., Miller R.S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., Bernard D., Zhang J., Lu Y., Gu Q., Shah R.B., Pienta K.J., Ling X., Kang S., Guo M., Sun Y., Yang D., Wang S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3933-3938.
187. Chen Q., Xie W., Kuhn D.J., Voorhees P.M., Lopez-Girona A., Mendy D., Corral L.G., Krenitsky V.P., Xu W., Moutouh-de Parseval L., Webb D.R., Mercurio F., Nakayama K.I., Nakayama K., Orlowski R.Z. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008, 111:4690-4699.
188. Orlicky S., Tang X., Neduva V., Elowe N., Brown E.D., Sicheri F., Tyers M. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol. 2010, 28:733-737.
189. Wu L., Grigoryan A.V., Li Y., Hao B., Pagano M., Cardozo T. Specific Small Molecule Inhibitors of Skp2-Mediated p27 Degradation. Chem. Biol. 2012, 19:1515-1524.
190. Aghajan M., Jonai N., Flick K., Fu F., Luo M., Cai X., Ouni I., Pierce N., Tang X., Lomenick B., Damoiseaux R., Hao R., Del Moral P.M., Verma R., Li Y., Li C., Houk K.N., Jung M.E., Zheng N., Huang L., Deshaies R.J., Kaiser P., Huang J. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 2010, 28:738-742.
191. Deshaies R.J., Joazeiro C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78:399-434.
192. Ma W.W., Messersmith W.A., Dy G.K., Weekes C.D., Whitworth A., Ren C., Maniar M., Wilhelm F., Eckhardt S.G., Adjei A.A., Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin. Cancer Res. 2012, 18:2048-2055.